Africa Home To 65% Of Global HIV Cases, Says WHO
|
"While an HIV vaccine remains elusive, lenacapavir is
the next best thing: a long-acting antiretroviral shown in trials to
prevent almost all HIV ... |
HIV-1 Vaccine Shows Strong T-Cell Response in Phase 1 Study
The experimental HIV vaccine regimen exhibited an acceptable safety profile and elicited robust immune responses in 99% of trial participants from ... View article...